5-Fu/LV联合奥沙利铂或羟基喜树碱对胃癌辅助化疗的临床观察

Clinical Observation of 5-Fu/LV in Combination with Oxaliplatin or HCPT for Gasitric Cancer

摘要: 目的比较奥沙利铂联合5-Fu/LV或羟基喜树碱联合5-Fu/LV对进展期胃癌根治切除后辅助化疗的疗效。方法79例III期胃癌根治切除后患者接受治疗,其中Oxaliplatin+5-Fu/LV方案(奥沙利铂组)40例,HCPT+5-Fu/LV方案(羟基喜树碱组)39例,病人一般特征经χ2检验,两组具有可比性(P>0.05)。结果奥沙利铂组三年生存率87.5%,羟基喜树碱组三年生存率69.2%,两组三年生存率差异有显著性(P<0.05)。毒副反应两组Ⅰ~II外周神经毒性有显著性差异,Oxaliplatin组为62.9%,HCPT组为31.6%(P<0.05),其他毒副反应的差异无显著性(P>0.05)。结论奥沙利铂联合5-Fu/LV对III期胃癌术后辅助化疗效果确切,毒副反应可耐受,不失为进展期胃癌根治切除后辅助化疗的较好选择。

Abstract: Objective To compare the novel neoadjuvant approach of Oxaliplatin and 5-Fu/LV with the approach of HCPT and 5-Fu/LV for patients with advanced gastric carcinoma excised completely, and evaluate the 3-year livability and the adverse reaction. Methods 79 patients suffered gastric carcinoma excised accepted the treatment. Among those, 40 were treated by the approach of Oxaliplatin and 5-Fu/LV. 39 were treated by the approach of HCPT and 5-Fu/LV. The patients statistic characters were tested by χ 2. These two ...